No Data
No Data
Botuo Biotech: Botuo Biotech\'s 2024 annual results forecast
Botuo Biotech 2024 Annual Results Forecast
Botao Biotechnology (688767.SH): Net income is expected to increase by approximately 59.47% in 2024.
On January 23, Gelonghui reported that Botao Biotechnology (688767.SH) announced its annual earnings forecast for 2024. According to preliminary calculations by the finance department, it is expected that the net income attributable to the parent company's owners will be around 170 million yuan in 2024, an increase of approximately 59.47% year-on-year. The net income attributable to the parent company's owners after deducting non-recurring gains and losses is expected to be around 119 million yuan, an increase of approximately 49.83% year-on-year. The company continues to focus on the POCT in-vitro diagnostics sub-industry, effectively grasping customer needs and actively expanding domestic and international markets.
Bohuo Bio (688767.SH) will distribute 5 yuan for every 10 shares in the first three quarters, with the equity registration date on January 9.
Bote Biological (688767.SH) issued an announcement that the company will implement equity distribution for the first three quarters of 2024, with each share...
Net income sharply declined with the contraction of overseas sales, Botai Biology opens up the microfluidic testing field | Earnings conference
①The rapid decline in overseas income dragged down the performance of Botuo Life Sciences, with overall revenue significantly decreasing compared to before the epidemic, and net income attributable to shareholders has decreased year-on-year for multiple years; ② Considering changes in the external environment, Botuo Life Sciences has terminated two major core investment projects, added the Microfluidic Fluorescence Detection Platform project, and ventured into the microfluidic technology field.
Botuo Biotech Report for the Third Quarter of 2024